INVESTORS REPORT

The
Synthetic
Miracle
The Revolutionary Flu Cure Set to Inject
a 25-Fold Boost into Your Portfolio

File Number
File Type

Confidential

Open Access

Investors Report

From: Michael A. Robinson

For: Nova-X Report Subscribers

The Synthetic Miracle:

The Revolutionary Flu Cure Set to Inject a
250-Fold Boost into Your Portfolio
Dear Nova-X Report Reader,
Weve all seen the headlines.
The flu has made its annual visit to the U.S., reacquainting itself with
your kids, spouse, parents, friends, and co-workers.
But this strain has been especially nasty, resulting in shortages of the
very vaccines that might have moderated its effects.
One of my colleagues here - an editor with a young son - finally got
his just last week - only because he stubbornly went to the same Rite-Aid
every single morning for an entire week.
Im sure you have similar stories you could share.
When you think about it, this years flu season illustrates one of the
great ironies of our time.
Although advances in medical technology have enabled us to create
the vaccines that so far have kept the yearly viral visit in check, the
reality is that those advances have been leapfrogged by global travel, an
advancement that makes a pandemic more likely than ever before.
Fortunately, there is an answer - an innovation that savvy investors
can play for windfall profits. Im going to show you how to grab those
profits for yourself.

IMMEDIATE ATTENTION REQUIRED

For the most recent and up-to-date information
please visit www.moneymappress.com

the NOva-X Report

Investors Report

But first we need to really understand the challenge at hand.

Let me show you what I mean.
At the start of each flu season, I literally count the days until I see
the first mention of the Spanish Flu pandemic of 1918. I understand the
attention it gets: Not only was it the worst flu outbreak in modern times,
it is thought to have killed between 20 million and 50 million people.
By that standard, the SARS crisis of 2003 was a drop in the bucket.
It killed less than 1,000 people around the world. But it cost a
fortune. The World Bank estimates the total hit to the global economy at
some $33 billion.
No wonder health officials urge us to get flu shots...
Then came the vaccines - which, as it turns out, are actually like a page
from history. The technology is decades old. Many vaccines stem from
portions of viruses grown in chicken eggs - not exactly cutting-edge tech.
But the new generation of flu vaccines Im going to show you right
now will change that.
They are cutting-edge tech. And they will help checkmate the
advantages that global travel had granted to the flu virus - restoring
balance in the process.
These new vaccines are synthetic, meaning they stem from fragments
of manmade DNA. In essence, they are programmed to fight the flu or
other designated diseases.
I see this as disruptive technology that will turn the $30 billion
vaccine market inside out. Besides the flu, firms in this space are working
on synthetic vaccines for leukemia, HIV, malaria, hepatitis, and cancer.
Yet one company shines above the rest. Im talking about Inovio
Pharmaceuticals Inc. (NYSE: INO)
Inovio has great science. Thats why the firm has received millions in
backing for its anti-malaria vaccine from a group affiliated with Bill and
Melinda Gates.
2

thE NOVA-X REport

Investors Report

Inovio also is working on a synthetic universal flu vaccine. And

its other projects include, but arent limited to, vaccines for leukemia
and cervical cancer. And it has another hook in the market. Its a novel
process of giving injections known as electroporation.
In laymens terms, electroporation works like this: the patient
receives the synthetic vaccine via an injection. But heres the secret
sauce as the shot is given, the patient also receives a short electric
pulse.
This burst of electricity causes cell membranes to open briefly to
accept the DNA rather than try to fight it as a foreign substance. In turn,
those cells produce antigens that tell the immune system to fight the
targeted disease.
Not only is this great science, but I think it will work as a strong
sales hook for future deals.
Not long ago, I had dinner with CEO and co-founder J. Joseph Kim.
Hes an award-winning scientist and former vaccine exec at Merck &
Co. Inc. (NYSE:MRK). And he studied under one of the towering giants
of biotech, Robert Langer, a distinguished professor at MIT.
When I had dinner, Kim was largely unknown outside the synthetic
vaccine sector of the biotech industry.
But he recently snagged a deal with Roche Holding AG (OTC:
RHHBY) that could be worth $422.5 million.
And now Kim firmly believes his companys stock is undervalued
at under $2 share.
I agree...
Fact is, Kim now has the chance to line up similar arrangements with
other Big Pharma players that could net another $800 million or even
more.
Were talking a deal pipeline that could be worth revenues of $1.2
billion for a firm with a market cap of just $480 million... and a firm that
still has no products on the market.
3

the NOva-X Report

Investors Report

We met for dinner at Bix, one of San Franciscos swankier

restaurants, located on the edge of the Financial District.
As I listened to Kim update me over a meal of steak and crab rolls, I
couldnt help but be struck by how much momentum Inovio has built up
in such a short amount of time.
For Inovio and the entire synthetic vaccine space that could be
worth some $30 billion in the next few years the Roche deal was
nothing short of a game changer...
But dont take my word for it. During a conference call following the
Roche news, industry analysts on the line all but openly applauded.
Under the deal, Inovio is granting Roche the exclusive rights to just
two products still in the early, investigative stages of clinical trials. The
licenses cover synthetic vaccines designed to treat prostate cancer (INO
5150) and hepatitis B (INO 1800).
Roche also gains the non-exclusive rights to Inovios patented
electroporation process to deliver the vaccines.
Inovio has several other drugs involved in clinical trials that I believe
will draw more ventures with Big Pharma if not an outright takeover
offer.
Under the Roche deal, the drug giant immediately funds Inovio with
$10 million. Inovio becomes eligible for the rest of the money as it hits
key milestones on the road to FDA approval for those two products.
Moreover, Roche also takes over financing for both drug programs. It
will continue to fund them from the current Phase I trials through Phase
III and into full commercialization.
But Kim is quick to point out that hes free to pursue similar
arrangements with its drug candidates for other forms of cancers as well
as HIV and additional infectious diseases.
Roche wasnt the only player interested in those products, Kim told
me. We had parallel discussions with other well-known names in Big
Pharma.
4

thE NOVA-X REport

Investors Report

I dont want to diminish the impact of this deal because it is our first
one of this magnitude and approach. But these were early stage products.
We were able to keep our lead programs intact.
The analogy I would use is that we traded away a couple of our
young draft picks but we have many more coming behind those.
As a result, Kim says INO still has plenty of room to run. He bases
that on a comparison with a biotech firm that trades at more than 25
times that of Inovio.
Alnylam Pharmaceuticals Inc. (NasdaqGS:ALNY) also is an earlystage biotech firm. It is focused on creating orphan drugs to treat serious
diseases.
From a scientific standpoint, the two firms are mirror images of
each other. Inovio is focused on synthetic DNA while Alnylam targets
therapies based on RNA interference.
DNA contains genetic instructions needed for the bodys proper
functioning. RNA on the other hand, is involved in protein synthesis and
also in transmitting genetic instructions.
From the standpoint of market cap and share price, the two couldnt
be more different.
With a market cap of more than $4 billion, ALNY trades at $53 a
share despite the fact that it is losing money and has negative cash flow.
So even if INO traded at just 20% of the value of ALNY, that would
mean a stock price of around $10.50 a share, for a gain of roughly 400%.
We have a higher upside and a lower market cap, Kim says.
Certainly that bodes very well our shareholders right now and for those
in the future.
Ive watched Inovio and its progress for the last several months. With
the Roche deal, it has cleared a major hurdle for me as a trader stable
cash flow. I believe Inovio has a huge upside ahead.

Please Note: From time to time, Money Map Press will recommend stocks or other investments
that will not be included in our regular portfolios. There are certain situations where we feel a
company may be an extraordinary value but may not necessarily fit within the selection guidelines
of these existing portfolios. In these cases, the recommendations are speculative and should not be
considered as part of Money Map Press philosophy.
Also, by the time you receive this report, there is a chance that we may have exited a recommendation
previously included in our portfolio. Occasionally, this happens because we use a disciplined selling
strategy with our investments, meaning that if a companys share price falls below a certain price
level, we immediately notify our subscribers to sell the stock.

NOTE: Money Map Press is not a broker, dealer or licensed investment advisor. No person listed here should
be considered as permitted to engage in rendering personalized investment, legal or other professional
advice as an agent of Money Map Press. Money Map Press does not receive any compensation for these
services. Additionally, any individual services rendered to subscribers by those mentioned are considered
completely separate from and outside the scope of services offered by Money Map Press. Therefore if you
choose to contact anyone listed here, such contact, as well as any resulting relationship, is strictly between
you and them.
Copyright 2007-present, Money Map Press, 16 W. Madison Street, Baltimore, MD 21201
Phone: 888.384.8339 or 410.226.2069
All rights reserved. Money Map Press provides its members with unique opportunities to build and protect wealth,
globally, under all market conditions. The executive staff, research department and editors who contribute to
Money Map Press recommendations are proud of our history and reputation. We believe the advice presented to
our subscribers in our published resources and at our meetings and seminars is the best and most useful available to global investors today. The recommendations and analysis presented to members is for the exclusive use
of members. Copying or disseminating any information published by Money Map Press, electronic or otherwise,
is strictly prohibited. Members should be aware that investment markets have inherent risks and there can be
no guarantee of future profits. Likewise, past performance does not assure future results. Recommendations are
subject to change at any time, so members are encouraged to make regular use of the website and pay special
attention to Money Map Press updates sent out via e-mail. The publishers, editors, employees or agents are not
responsible for errors and/or omissions.

Privacy Notice
You and your family are entitled to review and act on any recommendations made in this document. All Money
Map Press publications are protected by copyright. No part of this report may be reproduced by any means (including facsimile) or placed on any electronic medium without written permission from the publisher. Information
contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. Money
Map Press expressly forbids its writers from having a financial interest in any security recommended to its readers. All Money Map Press employees and agents must wait 24 hours after an Internet publication and 72 hours
after a print publication is mailed prior to following an initial recommendation. Money Map Press does not act as
a personal investment advisor, nor does it advocate the purchase or sale of any security or investment for any
specific individual. Investments recommended in this publication should be made only after consulting with your
investment advisor, and only after reviewing the prospectus or financial statements of the company.
Money Map Press 16 W. Madison Street Baltimore, MD 21201 888.384.8339 or 410.226.2069
NVX1113-203

WEB